What question did this study set out to answer?

The aim is to evaluate the effectiveness of TCR-T cell therapy targeting mutant KRAS in pancreatic cancer using humanized models.

Abstract A035: TCR-T cell therapy targeting mutant KRAS in pancreatic cancer using a humanized co-culture and mouse model system

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the effectiveness of TCR-T cell therapy targeting mutant KRAS in pancreatic cancer using humanized models.
Developed a humanized co-culture and mouse model system with engineered tumor and T cells.
Transduced murine KPC and human PDAC cell lines to express chimeric human-mouse HLA-A*11.01 proteins.
Co-cultured engineered T cells with tumor cell lines presenting mKRAS epitopes.
Assessed T cell activation through IFN-γ production and evaluated tumor growth in vivo after T cell transfer.
Engaged T cells recognized and activated by both natural and overexpressed mKRAS epitopes in vitro.
In vivo studies showed significantly reduced tumor growth with mKRAS-specific T cells in the presence of overexpressed mKRAS.
Relapsed tumors predominantly showed a lack of mKRAS epitope expression, indicating antigen loss as a treatment failure mechanism.

No takes yet. Share an insight, caveat, or question.

This preclinical assessment reveals tumor growth control in pancreatic cancer via TCR-T cell therapy targeting KRAS.

Hilfenhaus et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark